Differential expression of centromere protein K in triple negative breast cancer.

Triple Negative ◽

Primary Tumors ◽

Ductal Cells ◽

Centromere Protein

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding centromere protein K, CENPK, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). CENPK was also differentially expressed in bulk tumor in human breast cancer (3). CENPK mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of CENPK in primary tumors of the breast was correlated with recurrence-free survival in patients with basal-like and luminal A type cancer, while within triple negative breast cancer, primary tumor expression of CENPK was correlated with overall survival in patients with basal-like 2 subtype disease. CENPK may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of centromere protein U in triple negative breast cancer.

10.31219/osf.io/bxf3k ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Primary Tumors ◽

Ductal Cells ◽

Centromere Protein

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding centromere protein U, CENPU, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). CENPU was also differentially expressed in bulk tumor in human breast cancer (3). CENPU mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of CENPU in primary tumors of the breast was correlated with recurrence-free survival in patients with luminal A type cancer, while within triple negative breast cancer, primary tumor expression of CENPU was correlated with overall survival in patients with immunomodulatory and luminal androgen receptor subtype disease. CENPU may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of histone cluster 1, H2bh in triple negative breast cancer.

10.31219/osf.io/2drm5 ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Differential Expression ◽

Tumor Cells ◽

Survival Data ◽

Triple Negative ◽

Primary Tumors ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding histone cluster 1, H2bh, HIST1H2BH, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). HIST1H2BH was also differentially expressed in the brain metastases of patients with metastastic breast cancer (3). HIST1H2BH mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of HIST1H2BH in primary tumors of the breast was correlated with overall survival in patients with luminal A type cancer, while within triple negative breast cancer, primary tumor expression of HIST1H2BH was correlated with distant metastasis-free survival in patients with immunomodulatory subtype disease. HIST1H2BH may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of RecQ-like helicase 4 in triple negative breast cancer.

10.31219/osf.io/kphyr ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Primary Tumors ◽

Free Survival ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding RecQ-like helicase 4, RECQL4, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). RECQL4 was also differentially expressed in bulk tumor in human breast cancer (3). RECQL4 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of RECQL4 in primary tumors of the breast was correlated with recurrence-free survival in patients with HER2+ type cancer, while within triple negative breast cancer, primary tumor expression of RECQL4 was correlated with distant metastasis-free survival in patients with basal-like 2 subtype disease. RECQL4 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of H2A histone family member Z in triple negative breast cancer.

10.31219/osf.io/9kdcq ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Family Member ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Primary Tumors ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding H2A histone family member Z, H2AFZ, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). H2AFZ was also differentially expressed in bulk tumor in human breast cancer (3). H2AFZ mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of H2AFZ in primary tumors of the breast was correlated with recurrence-free survival in patients with luminal A, luminal B, and basal-like subtype cancer, while within triple negative breast cancer, primary tumor expression of H2AFZ was correlated with overall survival in patients with basal-like 2 subtype disease. H2AFZ may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of histone cluster 3, H2a in triple negative breast cancer.

10.31219/osf.io/89ceb ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Primary Tumors ◽

Free Survival ◽

Women diagnosed with triple negative breast cancer are predicted to benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding histone cluster 3, H2a, HIST3H2A, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). HIST3H2A was also differentially expressed in bulk tumor in human breast cancer (3). HIST3H2A mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of HIST3H2A in primary tumors of the breast was correlated with recurrence-free survival in patients with luminal A and HER2+ type cancer, while within triple negative breast cancer, primary tumor expression of HIST3H2A was correlated with distant metastasis-free survival in patients with immunomodulatory, mesenchymal, and luminal androgen receptor subtype disease. HIST3H2A may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of histone cluster 1, H2bd in triple negative breast cancer.

10.31219/osf.io/5fcwd ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Primary Tumors ◽

Free Survival ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding histone cluster 1, H2bd, HIST1H2BD, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). HIST1H2BD was also differentially expressed in bulk tumor in human breast cancer (3). HIST1H2BD mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of HIST1H2BD in primary tumors of the breast was correlated with recurrence-free survival in patients with luminal A, HER2+ and normal-like subtype cancer, while within triple negative breast cancer, primary tumor expression of HIST1H2BD was correlated with distant metastasis-free survival in patients with basal-like 1 subtype disease. HIST1H2BD may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of NIMA-related kinase 2 in triple negative breast cancer.

10.31219/osf.io/ueadf ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Differential Expression ◽

Tumor Cells ◽

Survival Data ◽

Triple Negative ◽

Primary Tumors ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding NIMA-related kinase 2, NEK2, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). NEK2 was also differentially expressed in bulk tumor in human breast cancer (3). NEK2 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of NEK2 in primary tumors of the breast was correlated with distant metastasis-free survival in patients with luminal A type cancer, while within triple negative breast cancer, primary tumor expression of NEK2 was correlated with overall survival in patients with luminal androgen receptor and mesenchymal subtype disease. NEK2 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of claspin in triple negative breast cancer.

10.31219/osf.io/yucqr ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Differential Expression ◽

Tumor Cells ◽

Survival Data ◽

Triple Negative ◽

Primary Tumors ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding claspin, CLSPN, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). CLSPN was also differentially expressed in bulk tumor in human breast cancer (3). CLSPN mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of CLSPN in primary tumors of the breast was correlated with recurrence-free survival in patients with basal-like type cancer, while within triple negative breast cancer, primary tumor expression of CLSPN was correlated with overall survival in patients with basal-like 2 subtype disease. CLSPN may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of histone cluster 1, H2bo in triple negative breast cancer.

10.31219/osf.io/aphrb ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Primary Tumors ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding histone cluster 1, H2bo, HIST1H2BO, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). HIST1H2BO was also differentially expressed in bulk tumor in human breast cancer (3). HIST1H2BO mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of HIST1H2BO in primary tumors of the breast was correlated with overall survival in patients with basal-like and normal-like subtype cancer, while within triple negative breast cancer, primary tumor expression of HIST1H2BO was correlated with overall survival in patients with luminal androgen receptor subtype disease. HIST1H2BO may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Differential expression of histone cluster 1, H2ag in triple negative breast cancer.

10.31219/osf.io/t8swk ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative ◽

Receptor Subtype ◽

Primary Tumors ◽

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding histone cluster 1, H2ag, HIST1H2AG, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). HIST1H2AG was also differentially expressed in bulk tumor in human breast cancer (3). HIST1H2AG mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of HIST1H2AG in primary tumors of the breast was correlated with post-progression survival in patients with basal-like type cancer, while within triple negative breast cancer, primary tumor expression of HIST1H2AG was correlated with recurrence-free survival in patients with basal-like 1 and luminal androgen receptor subtype disease. HIST1H2AG may be of relevance to initiation, maintenance or progression of triple negative breast cancers.